Who makes Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）?

Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） is developed by Mingzhi Zhang.

What development phase is Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） in?

Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）

Mingzhi Zhang · FDA-approved active Small molecule Quality 0/100

Modified SMILE, a combination therapy developed by Mingzhi Zhang, is currently marketed for an unspecified primary indication. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of detailed revenue and clinical trial data poses a significant risk in assessing the drug's market performance and competitive landscape.

At a glance

Generic name	Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
Also known as	Modified SMILE regiment
Sponsor	Mingzhi Zhang
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） CI brief — competitive landscape report
Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） updates RSS · CI watch RSS
Mingzhi Zhang portfolio CI